The French pharmaceutical company Servier, once a cardiology-focused firm, is rapidly transforming into an oncology contender through a calculated series of multi-billion dollar acquisitions, the latest being Day One Biopharmaceuticals.
At the Citizens Life Sciences Conference, Coherus Oncology detailed its strategic pivot from biosimilars to a focused immuno-oncology player, driven by the growth of LOQTORZI and two promising clinical assets acquired from Surface Oncology.
Buoyed by a 90% reduction in debt and surging revenue, Coherus Oncology outlines ambitious commercial and clinical plans for its flagship drug LOQTORZI and pipeline assets, aiming to solidify its position in the competitive oncology market.
French drugmaker Servier has agreed to acquire Day One Biopharmaceuticals for approximately $2.5 billion, gaining an approved pediatric brain cancer therapy and a pipeline of experimental drugs to strengthen its growing oncology portfolio.
Evolent Health delivered fourth-quarter results at the high end of its forecast, driven by disciplined cost management and organic growth. The company outlined an ambitious 2026 outlook, projecting 30% revenue growth, while navigating headwinds from contract transitions and a strategic pivot to dominate the oncology value-based care market.
Indian pharmaceutical firm Sakar Healthcare reports a robust 62% year-on-year revenue jump for Q3 FY26, powered by its expanding oncology business and European market approvals, even as it navigates rising operational costs.
BioNTech appoints Kylie Jimenez as its first Chief People Officer, a strategic move aimed at building the organizational and cultural backbone for its ambitious transition into a multi-product oncology company by 2030.
Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.
A wave of positive analyst coverage is reframing Gilead Sciences' investment narrative, spotlighting its robust HIV business, expanding oncology pipeline, and a patent runway extending to 2036. The planned $7.8 billion acquisition of Arcellx further bolsters its cell therapy ambitions, though questions remain on execution and policy headwinds.
Amgen reports significant advances in its KRAS inhibitor portfolio and a key biosimilar trial, reinforcing its long-term oncology strategy. As the company balances these capital-intensive developments with a steady dividend, investors assess the sustainability of its growth narrative amid a competitive landscape.
Gilead Sciences makes a bold $7.8 billion move to acquire cell therapy firm Arcellx, signaling a major strategic shift to diversify beyond its core HIV business and challenge rivals in the competitive oncology arena.
Jazz Pharmaceuticals closed 2025 with record-breaking revenue of $4.3 billion, driven by its sleep and epilepsy franchises. The company is navigating generic competition while advancing a promising oncology pipeline, highlighted by the potential 2024 launch of zanidatamab for gastric cancer.
Facing the impending patent expiry of its blockbuster drug Keytruda, Merck & Co. is aggressively deploying a three-pronged R&D strategy—spanning bispecifics, ADCs, and KRAS inhibitors—to secure its future in the competitive cancer therapy landscape.
At a recent industry summit, CRISPR Therapeutics executives detailed significant advances for its lead allogeneic CAR-T candidate, zugo-cel, revealing promising efficacy data and a parallel development strategy in oncology and autoimmune disorders, alongside discussions on pricing and global access.
BioNTech SE (BNTX) shares have rallied over 24% from December lows, prompting a rating downgrade from Leerink Partners. The firm maintains confidence in the company's long-term oncology strategy and robust cash position.
At a recent industry summit, Amgen executives detailed a focused R&D strategy in oncology, emphasizing T-cell engagers and precision small molecules. Key updates included the expanding commercial footprint of IMDELLTRA and pivotal late-stage trials for LUMAKRAS aimed at moving into earlier lines of therapy.
The Finnish pharmaceutical firm Orion Oyj has announced record 2025 sales and profits, proposing a significant dividend increase. The move highlights the company's strategic pivot to oncology, fueled by its Nubeqa partnership with Bayer, while raising questions about long-term earnings sustainability and capital allocation priorities.
Healthcare giant McKesson reported Q4 revenue of $106.2 billion, exceeding profit expectations and raising its full-year outlook, driven by oncology growth and strategic tech investments.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
AstraZeneca is strengthening its position in high-need therapeutic areas with key progress in immuno-oncology, breast cancer, and the imminent U.S. launch of a subcutaneous lupus therapy. The company's strategic execution in these fields is shaping its competitive edge and long-term valuation.
